5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to herein as “TFM compounds”) which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionizing radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; or (h) an inhibitor of a DNA damage repair enzyme.
1. A compound of the following formula, or a pharmaceutically acceptable salt thereof:
2. A compound of the following formula, or a pharmaceutically acceptable salt thereof:
3. A compound of the following formula, or a pharmaceutically acceptable salt thereof:
4. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier or diluent.
5. A pharmaceutical composition comprising a compound according to claim 2 , and a pharmaceutically acceptable carrier or diluent.
6. A pharmaceutical composition comprising a compound according to claim 3 , and a pharmaceutically acceptable carrier or diluent.
7. A pharmaceutical composition according to claim 4 , which is suitable for oral administration to a subject.
8. A pharmaceutical composition according to claim 5 , which is suitable for oral administration to a subject.
9. A pharmaceutical composition according to claim 6 , which is suitable for oral administration to a subject.
10. A method of preparing a pharmaceutical composition comprising the step of mixing a compound according to claim 1 , and a pharmaceutically acceptable carrier or diluent.
11. A method of preparing a pharmaceutical composition comprising the step of mixing a compound according to claim 2 , and a pharmaceutically acceptable carrier or diluent.
12. A method of preparing a pharmaceutical composition comprising the step of mixing a compound according to claim 3 , and a pharmaceutically acceptable carrier or diluent.
13. A method of treatment of a disease or condition that is mediated by CHK1 or a disease or condition that is ameliorated by the inhibition of CHK1 kinase function comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to claim 1 , claim 2 , or claim 3 .
14. A method of treatment comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound according to claim 1 , claim 2 , or claim 3 , wherein the treatment is treatment of:
a proliferative condition;
cancer;
head cancer; neck cancer; nervous system cancer; brain cancer; neuroblastoma; lung/mediastinum cancer; breast cancer; oesophagus cancer; stomach cancer; liver cancer; biliary tract cancer; pancreatic cancer; small bowel cancer; large bowel cancer; colorectal cancer; gynaecological cancer; genito-urinary cancer; ovarian cancer; thyroid gland cancer; adrenal gland cancer; skin cancer; melanoma; bone sarcoma; soft tissue sarcoma; paediatric malignancy; Hodgkin's disease; non-Hodgkin's lymphoma; myeloma; leukaemia; or metastasis from an unknown primary site;
lung cancer, breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, melanoma, glioma, or neuroblastoma;
MYC-amplified cancer;
c-MYC-amplified cancer;
MYCN-amplified cancer;
cancer characterised by overexpression of MYC;
cancer characterised by overexpression of MYCN;
cancer characterised by overexpression of c-MYC;
MYCN-amplified neuroblastoma;
c-MYC-amplified B cell lymphoma;
cancer characterised by increased endogenous replicative stress; or
cancer characterised by increased endogenous activation of CHK1 signalling.
15. A method according to claim 14 , wherein said administering is orally administering.
16. A method according to claim 14 , wherein the treatment further comprises administering to the subject one or more other agents selected from: (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionising radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; and (h) an inhibitor of a DNA damage repair enzyme.
17. A method of inhibiting CHK1 kinase function, in vitro or in vivo, comprising contacting a cell with an effective amount of a compound according to claim 1 , claim 2 , or claim 3 .
18. A method of inhibiting CHK1 kinase function in a cell, in vitro or in vivo, comprising contacting the cell with an effective amount of a compound according to claim 1 , claim 2 , or claim 3 .
19. A method of inhibiting cell proliferation, inhibiting cell cycle progression, promoting cell apoptosis, or a combination of one or more these, in vitro or in vivo, comprising contacting the cell with an effective amount of a compound according to claim 1 , claim 2 , or claim 3 .